Buy LIPO-C Injectable 10 mL Online | MIC Lipotropic Complex | Sterile Multi-Vial | SourceTides

Buy LIPO-C Injectable 10 mL Online from SourceTides.
LIPO-C is a multi-component lipotropic formulation supplied as a sterile, ready-to-use 10 mL aqueous solution in a sealed vial.
It combines seven individually characterised metabolic cofactors — L-Methionine, Myo-Inositol, Choline Chloride, L-Carnitine, Cyanocobalamin (B12), Pyridoxine HCl (B6), and Dexpanthenol (B5) — each targeting a distinct step in hepatic lipid metabolism, mitochondrial fatty acid oxidation, and one-carbon methylation biochemistry.
LIPO-C is not a single drug or a peptide. It is a compounded lipotropic reagent. Each component is individually characterised with its own published research base; the combination is designed to address multiple parallel rate-limiting steps in fat metabolism simultaneously rather than targeting a single pathway in isolation.
LIPO-C is widely used alongside GLP-1 receptor agonist research compounds in metabolic obesity and hepatic steatosis research protocols.
Every SourceTides 10 mL vial is sterile-filtered (0.22 µm), endotoxin-tested, pH-adjusted to 6.0–7.0, and ships with a full lot-specific Certificate of Analysis.
For in-vitro laboratory and preclinical research use only. Not for human consumption.

LIPO-C 10 mL — Formula and Technical Specifications

What Is LIPO-C?

LIPO-C stands for Lipotropic Complex — a name that describes its function rather than a single molecule. It is a multi-component injectable formulation combining seven metabolic cofactors into a single sterile solution, each targeting a different rate-limiting step in the pathway from stored body fat to cellular energy. Understanding LIPO-C requires understanding the pathway it targets.

Fat metabolism is not a single step. It is a multi-stage biochemical process: triglycerides must first be mobilised from adipose tissue, transported to the liver as fatty acids, packaged into lipoprotein particles (VLDL) for export, delivered to peripheral tissues, and then transported across the inner mitochondrial membrane before they can be burned for energy through beta-oxidation. Each stage has its own rate-limiting enzymes and cofactors. If any stage is deficient in substrate or cofactor, fat accumulates at that step. LIPO-C addresses six of these stages simultaneously.

The concept of lipotropic agents dates to the 1930s, when nutritional biochemists discovered that choline-deficient diets in animal models produced fatty liver (hepatic steatosis) — and that choline supplementation reversed it. The term “lipotropic” was coined to describe substances that prevent or reduce abnormal fat accumulation in the liver. Methionine and inositol were subsequently identified as additional lipotropic factors. The MIC (Methionine-Inositol-Choline) combination became the foundational lipotropic formula. L-Carnitine and B vitamins (B12, B6, B5) were added to extend the formula’s coverage from hepatic fat export to mitochondrial fat combustion and the methylation cycle that supports both.

The injectable format is important. Oral bioavailability of choline is moderate but incomplete; L-carnitine oral bioavailability is only 14–18% in higher doses; inositol is better absorbed but still subject to variable gut metabolism. Parenteral delivery bypasses all of these limitations, providing high and consistent plasma concentrations of all components simultaneously — the pharmacological rationale for injectable over oral in research settings. When you buy LIPO-C Injectable 10 mL from SourceTides, you get a sterile, ready-to-use research-grade formulation with confirmed concentrations for every component.

The Seven Components — Mechanisms and Research Rationale

Component 1 — L-Methionine: Methylation and VLDL Assembly

Methionine is an essential sulfur-containing amino acid — the body cannot synthesise it and must obtain it from dietary protein or supplementation. In the context of hepatic fat metabolism, methionine serves two critical roles. First, it is the precursor for S-adenosylmethionine (SAM) — the universal methyl donor in over 100 methylation reactions in the body. In fat metabolism specifically, SAM provides the methyl groups required for phosphatidylcholine (PC) synthesis via the PEMT (phosphatidylethanolamine N-methyltransferase) pathway. PC is the lipid that forms the outer shell of VLDL lipoprotein particles — the vehicles the liver uses to export triglycerides to peripheral tissues.

Second, methionine feeds into the transsulfuration pathway (with B6 as cofactor) to produce cysteine, taurine, and glutathione — the primary hepatic antioxidant. This is why methionine-choline-deficient (MCD) diets are the standard animal model for inducing NAFLD (now called MASLD): without methionine and choline, the liver cannot export fat or protect against oxidative stress, and rapidly accumulates lipid and inflammation. L-Carnitine supplementation has been shown to attenuate MCD diet-induced liver damage (Mollica et al. 2020; Dig Liver Dis), which is one of the mechanistic validations for the LIPO-C combination approach.

Component 2 — Myo-Inositol: Insulin Signalling and Phospholipid Synthesis

Myo-inositol is a carbocyclic sugar that serves two distinct metabolic roles relevant to lipid biology. Its primary structural role is as the head group of phosphatidylinositol (PI) — a phospholipid family that includes the critical signalling lipids PI(3,4,5)P3 and PI(4,5)P2. These PI species are the substrates and products of PI3-kinase (PI3K), the key intracellular mediator of insulin receptor signalling. The insulin signalling cascade — insulin receptor → IRS-1 → PI3K → PIP3 → Akt → GLUT4 translocation and protein synthesis — depends on adequate myo-inositol for PI synthesis. When inositol is limiting, PI3K cannot generate sufficient PIP3, and insulin signalling efficiency falls.

Clinical meta-analyses of myo-inositol supplementation in polycystic ovary syndrome (PCOS) — a condition defined by insulin resistance and metabolic dysfunction — demonstrate consistent improvements in insulin sensitivity, fasting glucose, and lipid profiles. A 2022 systematic review in Nutrients (PMID: 35408088) confirmed that myo-inositol significantly reduces fasting insulin and HOMA-IR compared to placebo. In hepatic research models, inositol acts synergistically with choline — both are required for proper phospholipid synthesis, and inositol deficiency compounds the fat accumulation caused by choline deficiency.

Component 3 — Choline Chloride: VLDL Particle Assembly and Membrane Integrity

Choline is the original lipotropic factor and the most critical single component in LIPO-C for hepatic fat metabolism. Choline is the precursor to phosphatidylcholine (PC) via the Kennedy (CDP-choline) pathway — one of the most conserved biosynthetic pathways in mammalian biology. PC constitutes approximately 70% of the phospholipid composition of the outer shell of all lipoprotein particles, including VLDL. Without sufficient choline to synthesise PC, the liver literally cannot package triglycerides into exportable VLDL particles. Triglycerides accumulate intracellularly. This is why choline deficiency is one of the fastest ways to induce experimental hepatic steatosis — it can produce measurable liver fat accumulation within days.

Beyond VLDL assembly, choline is the precursor to acetylcholine (via choline acetyltransferase) — the primary parasympathetic and neuromuscular junction neurotransmitter. In metabolic research, the cholinergic-hepatic axis is a growing research area: hepatic stellate cells express muscarinic acetylcholine receptors, and vagal cholinergic signalling modulates hepatic glucose production, lipid metabolism, and insulin sensitivity. The multi-functional role of choline — spanning lipoprotein biology, cell membrane integrity, and neural-hepatic signalling — makes it the broadest-acting single component in the LIPO-C formula.

Component 4 — L-Carnitine: The Mitochondrial Fatty Acid Shuttle

L-Carnitine’s role in LIPO-C is mechanistically distinct from the three MIC components. While methionine, inositol, and choline address hepatic fat export, L-carnitine addresses fat combustion in peripheral tissues — specifically the rate-limiting transport step that gets long-chain fatty acids (LCFAs) across the inner mitochondrial membrane into the mitochondrial matrix where beta-oxidation occurs.

LCFAs cannot cross the inner mitochondrial membrane in free form — the membrane is impermeable to them. The carnitine shuttle system converts LCFAs to acylcarnitine esters, which are recognised by the CPT1 (carnitine palmitoyltransferase 1) and CPT2 translocase system. CPT1 on the outer mitochondrial membrane converts LCFA-CoA to acylcarnitine; CACT (carnitine-acylcarnitine translocase) shuttles it across; CPT2 on the inner membrane converts it back to LCFA-CoA inside the matrix for beta-oxidation. Without sufficient L-carnitine, this shuttle cannot operate, LCFAs accumulate outside the mitochondria, and beta-oxidation stalls regardless of how efficiently the liver has exported fat.

A 2020 meta-analysis of L-carnitine supplementation trials in NAFLD patients (Front Nutr; Frontiers Nutrition 2026 review) confirmed that L-carnitine significantly reduces liver fat, ALT levels, and metabolic markers. In animal models, L-carnitine protects against the metabolic consequences of methionine-choline-deficient diets — providing direct experimental evidence of its complementary role to the MIC components.

Component 5 — Cyanocobalamin (B12): Methylation Cycle Closure and Propionate Metabolism

Vitamin B12 is the critical cofactor that “closes” the methylation cycle initiated by methionine. Methionine is converted to SAM (donating its methyl group), SAM becomes SAH (S-adenosylhomocysteine), and SAH is hydrolysed to homocysteine. Homocysteine can either be remethylated back to methionine (by methionine synthase, which requires B12 and methylfolate) or enter the transsulfuration pathway (with B6). Without B12, homocysteine accumulates — an independent cardiovascular risk factor — and the methylation cycle stalls, impairing SAM regeneration and reducing methyl group availability for all downstream methylation reactions including VLDL assembly.

B12 also serves as a cofactor for methylmalonyl-CoA mutase, which converts methylmalonyl-CoA (from odd-chain fatty acid and branched-chain amino acid catabolism) to succinyl-CoA for entry into the citric acid cycle. B12 deficiency causes methylmalonyl-CoA accumulation — a metabolite that competitively inhibits carnitine acetyltransferase and thereby impairs the very fatty acid oxidation that L-carnitine is present in LIPO-C to support. This is a direct biochemical rationale for including B12 in the LIPO-C formula alongside L-carnitine.

Component 6 — Pyridoxine HCl (B6): Transsulfuration and Amino Acid Metabolism

Pyridoxine (Vitamin B6) is the cofactor for cystathionine beta-synthase and cystathionine gamma-lyase — the two enzymes of the transsulfuration pathway that convert homocysteine into cysteine, and ultimately glutathione. In the LIPO-C context, B6 is critical for the methionine-homocysteine-cysteine pathway: without adequate B6, homocysteine cannot be efficiently shunted into the transsulfuration pathway, limiting cysteine and glutathione synthesis. Glutathione is the liver’s primary antioxidant. When hepatic steatosis is present, oxidative stress is high and glutathione demand is elevated — making adequate B6 (and methionine as its precursor substrate) particularly important for hepatic cytoprotection in metabolic liver disease research models.

Component 7 — Dexpanthenol (B5): Coenzyme A and Universal Acyl Carrier

Dexpanthenol is the alcohol form of pantothenic acid (Vitamin B5), converted in cells to 4′-phosphopantetheine and ultimately to Coenzyme A (CoA). CoA is the universal acyl carrier in metabolism — it is required for fatty acid activation (forming fatty acyl-CoA), for entry into the Krebs cycle (as acetyl-CoA), for cholesterol synthesis, and for amino acid catabolism. In the specific context of fat metabolism, every step of beta-oxidation produces acetyl-CoA, which enters the citric acid cycle or is used for ketogenesis. Every fatty acid must be activated to its CoA thioester before the carnitine shuttle can transport it into mitochondria. If CoA is limiting — as can occur during sustained fat mobilisation — beta-oxidation efficiency falls. Dexpanthenol in LIPO-C ensures CoA substrate availability for the metabolic flux the other components are driving.

LIPO-C Research Evidence: Individual Components

LIPO-C as a fixed-dose combination formulation does not have its own randomised controlled trial data — this is standard for compounded multi-nutrient formulations. However, each individual component has an independent research base. The table below summarises the strongest evidence for each.

The Lipotropic Pathway: Fat Mobilisation to Combustion

The metabolic pathway from stored body fat to cellular energy runs through six distinct stages. LIPO-C addresses five of them simultaneously — which is why multi-component lipotropic research formulas produce different results than single-agent interventions.

What Is LIPO-C Used for in Research?

LIPO-C vs Related Metabolic Research Compounds

LIPO-C Quality Control at SourceTides

Every batch of LIPO-C Injectable 10 mL undergoes the following QC tests before release. Because LIPO-C is a multi-component formulation in aqueous solution, quality control is more complex than single-component lyophilised peptides — each component must be individually verified and the combined solution must meet sterility and endotoxin specifications.

LIPO-C Regulatory Status

Peer-Reviewed References

Frequently Researched Alongside LIPO-C Injectable

LIPO-C is most commonly used alongside GLP-1 research compounds and metabolic longevity compounds in the following combinations:

• Semaglutide — GLP-1R agonist; reduces appetite and caloric intake; studied alongside LIPO-C in metabolic protocols combining GLP-1-mediated appetite suppression with LIPO-C’s hepatic lipid clearance and mitochondrial fat combustion support
• Tirzepatide — GLP-1R + GIP dual agonist; greater weight loss than Semaglutide; paired with LIPO-C for comprehensive metabolic research addressing appetite, insulin sensitivity, and lipid metabolism simultaneously
• Retatrutide — GLP-1R + GIP + Glucagon triple agonist; glucagon activation drives hepatic fat oxidation directly — mechanistic overlap with LIPO-C’s carnitine and CoA-mediated beta-oxidation pathway; studied together for maximum hepatic fat clearance research
• NAD⁺ Injectable — Sirtuin substrate; SIRT1/SIRT3 mitochondrial regulation; NAD⁺ drives the sirtuin-PGC-1α mitochondrial biogenesis axis while LIPO-C provides the carnitine-CoA substrate infrastructure for beta-oxidation — studied together in comprehensive mitochondrial metabolism and longevity research
• MK-677 Ibutamoren — Oral GH secretagogue; raises IGF-1; but consistently impairs insulin sensitivity; LIPO-C’s inositol component specifically addresses PI3K/Akt insulin signalling — studied together to examine GH axis activation with metabolic support
• Sermorelin 10 mg — GHRH agonist; GH axis; GH drives lipolysis in adipose tissue; LIPO-C provides the hepatic fat processing and mitochondrial combustion infrastructure needed to handle the freed fatty acids; complementary in body composition research
• Ipamorelin 10 mg — GH secretagogue without cortisol elevation; studied with LIPO-C in body composition protocols combining GH-driven lipolysis with lipotropic hepatic and mitochondrial fat processing
• BPC-157 Capsules — Gut and liver protective peptide; GI cytoprotection; BPC-157’s hepatoprotective and gut mucosal effects complement LIPO-C’s hepatic fat metabolism support in NASH and gut-liver axis research models
• Epithalon 10 mg — Pineal bioregulator; telomere biology; studied with LIPO-C in longevity panels combining cellular anti-ageing (Epithalon/telomerase) with metabolic anti-ageing (LIPO-C/mitochondrial fat oxidation and methylation)
• Thymalin 10 mg — Thymic immune bioregulator; T-cell differentiation; immune ageing; studied alongside LIPO-C and other longevity compounds in multi-system ageing protocols
• Kisspeptin-10 — HPG axis master regulator; LH/FSH/testosterone; studied alongside LIPO-C in metabolic-reproductive axis research where testosterone (Kisspeptin-driven) and lipid metabolism (LIPO-C) intersect in body composition models
• GLP-1 — Native GLP-1 peptide; pancreatic insulin secretion; gut-liver axis; studied alongside LIPO-C for native incretin vs LIPO-C lipotropic comparison in metabolic research designs

Frequently Asked Questions